Abstract
BackgroundTocilizumab (TCZ), an inhibitor of interleukin-6 (IL-6), has been widely used to treat rheumatic diseases such as rheumatoid arthritis (RA) and juvenile idiopathic arthritis. Recently, TCZ was approved for use...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have